JIGAR STEATOZI VA ARTERIAL BOSIMNING SUTKALIK RITMI: SEMIZLIK FENOTIPLARI KESIMIDA TAHLIL

Maksuda Zubaydullayeva; Umida Maxmudova; Nargiza Kadirova

Authors

Maksuda Zubaydullayeva son Oilaviy tibbiyotda ichki kasalliklar va preventiv tibbiyot asoslari kafedrasi dotsenti t.f.n., Toshkent davlat tibbiyot universiteti, Toshkent, O‘zbekiston Author
Umida Maxmudova 1-son Oilaviy tibbiyotda ichki kasalliklar va preventiv tibbiyot asoslari kafedrasi assistenti, Toshkent davlat tibbiyot universiteti, Toshkent, O‘zbekiston Author
Nargiza Kadirova 1-son Oilaviy tibbiyotda ichki kasalliklar va preventiv tibbiyot asoslari kafedrasi assistenti, PhD, Toshkent davlat tibbiyot universiteti, Toshkent, O‘zbekiston Author

Keywords:

jigar steatozi, jigar steatos indeksi (JSI), semizlik fenotiplari, arterial gipertenziya, sutkalik arterial bosim monitoringi

Abstract

Metabolik disfunksiya bilan bog‘liq steatozli jigar kasalligi kardiometabolik buzilishlar bilan chambarchas bog‘liq bo‘lib, arterial bosimning sutkalik ritmiga ta’siri yetarlicha o‘rganilmagan.

Semizlikning turli fenotiplarida jigar steatozini JSI indeksi orqali baholash va uning arterial bosimning sutkalik profili bilan bog‘liqligini aniqlash.

Tadqiqotga 40–65 yoshdagi 90 nafar semiz bemor jalb qilindi. Bemorlar metabolik sog‘lom (MSS) va metabolik nosog‘lom (MNS) guruhlarga ajratildi. Laborator ko‘rsatkichlar, JSI indeksi va sutkalik arterial bosim monitoringi natijalari tahlil qilindi.

MNS guruhida JSI indeksi sezilarli yuqori bo‘ldi (41.2 ± 3.1 ga nisbatan 32.4 ± 2.8; p < 0.001). Ushbu guruhda tungi arterial bosim ko‘rsatkichlari yuqori va “non-dipper” profili 68.9% hollarda kuzatildi. JSI indeksi yuqori bemorlarda tungi qon bosim ham mos ravishda yuqori bo’ldi.

Jigar steatozi og‘irligi arterial bosimning sutkalik ritmi buzilishi bilan bog‘liq. HSI indeksi kardiometabolik xavfi yuqori bemorlarni aniqlashda samarali invaziv bo‘lmagan vosita bo‘lishi mumkin.

Downloads

Download data is not yet available.

References

1. European Association for the Study of the Liver

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity.

Journal of Hepatology. 2021;75(3):659–689.

2. American Association for the Study of Liver Diseases

Practice guidance on the clinical assessment and management of NAFLD.

Hepatology. 2018;67(1):328–357.

3. O'Brien E., Parati G., Stergiou G.

European Society of Hypertension position paper on ambulatory blood pressure monitoring.

Journal of Hypertension. 2013;31:1731–1768.

4. Lee J.H., Kim D., Kim H.J.

Hepatic steatosis index: A simple screening tool reflecting nonalcoholic fatty liver disease.

Digestive and Liver Disease. 2010;42(7):503–508.

5. Eslam M, Newsome P.N., Sarin S.K. et al.

A new definition for metabolic dysfunction–associated fatty liver disease: An international expert consensus statement.

Journal of Hepatology. 2020;73(1):202–209.

6. Younossi Z.M., Koenig A.B., Abdelatif D. et al.

Global epidemiology of NAFLD—Meta-analytic assessment of prevalence, incidence, and outcomes.

Hepatology. 2016;64(1):73–84.

7. Targher G, Day C.P., Bonora E.

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease.

New England Journal of Medicine. 2010;363:1341–1350.

8. Marchesini G, Bugianesi E., Forlani G.

Nonalcoholic fatty liver disease: A feature of the metabolic syndrome.

Diabetes. 2001;50(8):1844–1850.

9. Абдумаликова, Ф. Б., Нуриллаева, Н. М., Зубайдуллаева, М. Т., & Хидоятова, М. Р. (2024). Использование инновационных способов ранней диагностики заболеваний внутренних органов в первичном звене здравоохранения.

10. Zubaydullayeva, M. T., Maxmudova, U. R., Majidov Sh, X., & Karimova, M. T. (2025). METABOLIK SINDROMI BILAN BEMORLARDA TOMIR YOSHINI BAHOLASH.

11. Зубайдуллаева, М. Т., Махмудова, У. Р., & Мажидов, Ш. Х. (2025). ОЦЕНКА СОСУДИСТОГО ВОЗРАСТА У ПАЦИЕНТОВ С МЕТАБОЛИЧЕСКИМ СИНДРОМОМ.

12. Нуриллаева, Н. М., Махмудова, У. Р., Зубайдуллаева, М. Т., & Кенжаев, С. Р. (2025). ОСОБЕННОСТИ ТЕЧЕНИЯ ЛЁГОЧНОЙ ГИПЕРТЕНЗИИ У БОЛЬНЫХ С СЕРДЕЧНОЙ НЕДОСТАТОЧНОСТЬЮ.